X4 Pharmaceuticals Inc (XFOR) — Cash Flow-to-Debt Ratio
X4 Pharmaceuticals Inc (XFOR) has a Cash Flow-to-Debt Ratio of -0.19x as of March 2026, meaning its operating cash flow of $-19.60 Million could theoretically repay 0% of its total liabilities ($101.83 Million) in one year. Check X4 Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
X4 Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for X4 Pharmaceuticals Inc across 11 annual periods. Also explore X4 Pharmaceuticals Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for X4 Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for X4 Pharmaceuticals Inc. For market capitalisation and broader financial context, see X4 Pharmaceuticals Inc (XFOR) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-85.62 Million | $104.17 Million | ▲ +22.0% |
| 2024 | -1.05x | $-130.90 Million | $124.30 Million | ▼ -4.9% |
| 2023 | -1.00x | $-96.51 Million | $96.16 Million | ▼ -6.1% |
| 2022 | -0.95x | $-77.10 Million | $81.53 Million | ▲ +29.6% |
| 2021 | -1.34x | $-70.91 Million | $52.76 Million | ▼ -14.4% |
| 2020 | -1.17x | $-58.82 Million | $50.07 Million | ▲ +23.1% |
| 2019 | -1.53x | $-48.05 Million | $31.48 Million | ▲ +13.5% |
| 2018 | -1.76x | $-25.42 Million | $14.40 Million | ▼ -42.8% |
| 2017 | -1.24x | $-27.87 Million | $22.55 Million | ▼ -39.0% |
| 2016 | -0.89x | $-21.64 Million | $24.33 Million | ▼ -14.2% |
| 2015 | -0.78x | $-10.82 Million | $13.88 Million | — |